Can Fite Biopharma Ltd (CANF) - Cash Flow Conversion Efficiency

Latest as of June 2025: -0.568x

Based on the latest financial reports, Can Fite Biopharma Ltd (CANF) has a cash flow conversion efficiency ratio of -0.568x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA-2.38 Million ≈ $-6.37K USD) by net assets (ILA4.18 Million ≈ $11.22K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see CANF company net worth for the company's overall valuation and market capitalisation.

Can Fite Biopharma Ltd - Cash Flow Conversion Efficiency Trend (2010–2025)

This chart illustrates how Can Fite Biopharma Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Can Fite Biopharma Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Can Fite Biopharma Ltd ranked by their cash flow conversion efficiency. See CANF operating cash to total liabilities to evaluate how effectively operating cash flow covers total debt obligations.

Company	Cash Flow Conversion Efficiency
DFS Furniture PLC LSE:DFS	0.354x
Roman DBDR Acquisition Corp. II Warrants NASDAQ:DRDBW	N/A
Autonomix Medical, Inc. Common Stock NASDAQ:AMIX	-1.121x
Golden State Mining Ltd AU:GSM	-1.834x
Ohmyhome Limited Ordinary Shares NASDAQ:OMH	-0.507x
SRJ Technologies Group Plc AU:SRJ	-0.052x
Applied DNA Sciences Inc NASDAQ:APDN	-0.403x
Prima Alloy Steel Universal JK:PRAS	0.006x

Annual Cash Flow Conversion Efficiency for Can Fite Biopharma Ltd (2010–2025)

The table below shows the annual cash flow conversion efficiency of Can Fite Biopharma Ltd from 2010 to 2025. View CANF stock price for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	ILA5.59 Million ≈ $15.00K	ILA-9.69 Million ≈ $-25.97K	-1.732x	-23.28%
2024-12-31	ILA5.44 Million ≈ $14.57K	ILA-7.64 Million ≈ $-20.47K	-1.405x	-3.92%
2023-12-31	ILA6.24 Million ≈ $16.74K	ILA-8.44 Million ≈ $-22.63K	-1.352x	+44.03%
2022-12-31	ILA4.47 Million ≈ $11.99K	ILA-10.80 Million ≈ $-28.96K	-2.415x	-252.36%
2021-12-31	ILA14.38 Million ≈ $38.56K	ILA-9.86 Million ≈ $-26.43K	-0.685x	+65.49%
2020-12-31	ILA6.07 Million ≈ $16.28K	ILA-12.06 Million ≈ $-32.34K	-1.986x	+55.24%
2019-12-31	ILA2.44 Million ≈ $6.55K	ILA-10.83 Million ≈ $-29.05K	-4.437x	-221.93%
2018-12-31	ILA3.02 Million ≈ $8.08K	ILA-4.16 Million ≈ $-11.14K	-1.378x	+55.81%
2017-12-31	ILA3.05 Million ≈ $8.19K	ILA-9.52 Million ≈ $-25.53K	-3.118x	-35.33%
2016-12-31	ILA3.87 Million ≈ $10.39K	ILA-8.93 Million ≈ $-23.93K	-2.304x	-417.41%
2015-12-31	ILA10.44 Million ≈ $28.00K	ILA-4.65 Million ≈ $-12.47K	-0.445x	+58.32%
2014-12-31	ILA6.86 Million ≈ $18.38K	ILA-7.33 Million ≈ $-19.64K	-1.069x	+44.80%
2013-12-31	ILA4.46 Million ≈ $11.95K	ILA-8.63 Million ≈ $-23.14K	-1.936x	-131.52%
2012-12-31	ILA-707.99K ≈ $-1.90K	ILA-4.35 Million ≈ $-11.66K	6.141x	+467.80%
2011-12-31	ILA3.29 Million ≈ $8.82K	ILA-5.50 Million ≈ $-14.73K	-1.670x	-497.22%
2010-12-31	ILA13.07 Million ≈ $35.05K	ILA-3.65 Million ≈ $-9.80K	-0.280x	--

About Can Fite Biopharma Ltd

TA:CANF Israel Biotechnology

Market Cap

$4.00 Million

ILA1.49 Billion ILA

Market Cap Rank

#29096 Global

#420 in Israel

Share Price

ILA348.00

Change (1 day)

+1.69%

52-Week Range

ILA1.00 - ILA1500.00

All Time High

ILA1500.00